FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897589344> ?p ?o ?g. }

• W2897589344 endingPage "255" @default.
• W2897589344 startingPage "246" @default.
• W2897589344 abstract "Background Ideally, vasodilator therapies for pulmonary arterial hypertension (PAH) should have a favorable impact on markers of vascular dysfunction, in addition to their known effects on hemodynamics, cardiac function, and patient’s physical capacity. Methods We analyzed circulating (plasma) markers of endothelial and platelet activation/dysfunction (enzyme-linked immunoassays) in the specific setting of advanced PAH associated with congenital heart disease, during the course of sildenafil and tadalafil therapies. Thirty-one patients were enrolled (age 10-54 years), most of them with chronic hypoxemia and elevated hematocrit. Drugs were administered orally for 6 months (sildenafil [n = 16], 20 mg t.i.d.; tadalafil [n = 15], single daily dose of 40 mg). Measurements were performed at baseline, and 90 and 180 days. Results Compared to controls, patients had elevated baseline β-thromboglobulin (β-TG, P = .002), P-selectin (P = .027), tissue-type plasminogen activator (t-PA, P = .009), and von Willebrand factor antigen (VWF:Ag, P = .010). Thrombomodulin was importantly reduced (TM, P < .001), while soluble CD40 Ligand was not changed (P = .320). Tadalafil administration was associated with improvement of β-TG (P = .004), t-PA (P = .003) and TM (P = .046) levels, while P-selectin was improved by sildenafil treatment only (P = .034). VWF:Ag improved transiently in the sildenafil group (P = .019). Both therapies were associated with improvement of the physical capacity (functional class and distance walked during the 6-minute test, P < .05), hematocrit and hemoglobin level (P < .05), and health-related quality of life (physical and mental components, P < .05). Conclusion In PAH associated with congenital heart disease, phosphodiesterase 5 inhibitors seem to have beneficial actions at microcirculatory level, beyond the proposed effects as vasodilators." @default.
• W2897589344 created "2018-10-26" @default.
• W2897589344 creator A5000550562 @default.
• W2897589344 creator A5024170031 @default.
• W2897589344 creator A5029023934 @default.
• W2897589344 creator A5048428171 @default.
• W2897589344 creator A5060215294 @default.
• W2897589344 date "2018-10-20" @default.
• W2897589344 modified "2023-10-10" @default.
• W2897589344 title "Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease" @default.
• W2897589344 cites W1584838791 @default.
• W2897589344 cites W1978449362 @default.
• W2897589344 cites W1978605412 @default.
• W2897589344 cites W1980732197 @default.
• W2897589344 cites W1982370353 @default.
• W2897589344 cites W2004008756 @default.
• W2897589344 cites W2010477466 @default.
• W2897589344 cites W2015441781 @default.
• W2897589344 cites W2058247963 @default.
• W2897589344 cites W2069786094 @default.
• W2897589344 cites W2078897386 @default.
• W2897589344 cites W2079000009 @default.
• W2897589344 cites W2086882211 @default.
• W2897589344 cites W2102614549 @default.
• W2897589344 cites W2111541126 @default.
• W2897589344 cites W2118143284 @default.
• W2897589344 cites W2134755416 @default.
• W2897589344 cites W2138807244 @default.
• W2897589344 cites W2143241675 @default.
• W2897589344 cites W2143276205 @default.
• W2897589344 cites W2148250060 @default.
• W2897589344 cites W2167947015 @default.
• W2897589344 cites W2171053424 @default.
• W2897589344 cites W2178190745 @default.
• W2897589344 cites W2331475731 @default.
• W2897589344 cites W2336807421 @default.
• W2897589344 cites W2365155867 @default.
• W2897589344 cites W2413833374 @default.
• W2897589344 cites W2492972926 @default.
• W2897589344 cites W2517447208 @default.
• W2897589344 cites W2616756578 @default.
• W2897589344 cites W2731558138 @default.
• W2897589344 cites W2739468434 @default.
• W2897589344 cites W2794402049 @default.
• W2897589344 cites W4292806894 @default.
• W2897589344 doi "https://doi.org/10.1111/chd.12688" @default.
• W2897589344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30343508" @default.
• W2897589344 hasPublicationYear "2018" @default.
• W2897589344 type Work @default.
• W2897589344 sameAs 2897589344 @default.
• W2897589344 citedByCount "7" @default.
• W2897589344 countsByYear W28975893442019 @default.
• W2897589344 countsByYear W28975893442020 @default.
• W2897589344 countsByYear W28975893442021 @default.
• W2897589344 countsByYear W28975893442023 @default.
• W2897589344 crossrefType "journal-article" @default.
• W2897589344 hasAuthorship W2897589344A5000550562 @default.
• W2897589344 hasAuthorship W2897589344A5024170031 @default.
• W2897589344 hasAuthorship W2897589344A5029023934 @default.
• W2897589344 hasAuthorship W2897589344A5048428171 @default.
• W2897589344 hasAuthorship W2897589344A5060215294 @default.
• W2897589344 hasConcept C126322002 @default.
• W2897589344 hasConcept C164705383 @default.
• W2897589344 hasConcept C2776768464 @default.
• W2897589344 hasConcept C2779394231 @default.
• W2897589344 hasConcept C2780816001 @default.
• W2897589344 hasConcept C2780930700 @default.
• W2897589344 hasConcept C2780959883 @default.
• W2897589344 hasConcept C2780972559 @default.
• W2897589344 hasConcept C3018697912 @default.
• W2897589344 hasConcept C71924100 @default.
• W2897589344 hasConcept C74534348 @default.
• W2897589344 hasConcept C89560881 @default.
• W2897589344 hasConcept C90924648 @default.
• W2897589344 hasConceptScore W2897589344C126322002 @default.
• W2897589344 hasConceptScore W2897589344C164705383 @default.
• W2897589344 hasConceptScore W2897589344C2776768464 @default.
• W2897589344 hasConceptScore W2897589344C2779394231 @default.
• W2897589344 hasConceptScore W2897589344C2780816001 @default.
• W2897589344 hasConceptScore W2897589344C2780930700 @default.
• W2897589344 hasConceptScore W2897589344C2780959883 @default.
• W2897589344 hasConceptScore W2897589344C2780972559 @default.
• W2897589344 hasConceptScore W2897589344C3018697912 @default.
• W2897589344 hasConceptScore W2897589344C71924100 @default.
• W2897589344 hasConceptScore W2897589344C74534348 @default.
• W2897589344 hasConceptScore W2897589344C89560881 @default.
• W2897589344 hasConceptScore W2897589344C90924648 @default.
• W2897589344 hasFunder F4320320997 @default.
• W2897589344 hasFunder F4320321091 @default.
• W2897589344 hasIssue "2" @default.
• W2897589344 hasLocation W28975893441 @default.
• W2897589344 hasLocation W28975893442 @default.
• W2897589344 hasOpenAccess W2897589344 @default.
• W2897589344 hasPrimaryLocation W28975893441 @default.
• W2897589344 hasRelatedWork W1983846584 @default.
• W2897589344 hasRelatedWork W2000730815 @default.
• W2897589344 hasRelatedWork W2008114203 @default.
• W2897589344 hasRelatedWork W2035736227 @default.

• next